MBX BIOSCIENCES INC

MBX Biosciences Q2 2026 earnings: $418M cash, $200M financing, and a growing pipeline of once‑monthly peptide therapies poised to reshape endocrine and metabolic markets.

MBX Biosciences’ 12‑month Canvuparatide trial shows sustained calcium control for chronic hypoparathyroidism, offering a weekly dosing alternative despite a recent stock dip.

MBX Biosciences clears FDA end‑of‑Phase 2 for once‑weekly canvuparatide, advancing to a Phase 3 trial for chronic hypoparathyroidism.

MBX Biosciences, a $1.38 billion biotech poised for a hypoparathyroidism breakthrough, will reveal Phase 2 canvuparatide data in Q2 2026, sparking a potential Phase 3 launch and investor momentum.

MBX Biosciences Inc’s stock price has been highly volatile, with a negative P/E ratio and a market capitalization of $377 million, raising questions about the company’s ability to deliver results and achieve profitability.